A 2 receptors; Epac; phosphoinositol-3 kinase; cardiac collagen deposition CARDIAC FIBROBLASTS (CF) synthesize and secrete components of the extracellular matrix (ECM), a complex network of connective tissue proteins that surrounds and interconnects cardiac cells (25, 27) . Main components of the cardiac ECM are fibrillar collagens type I and III (27) . Under normal physiological conditions, the ECM preserves cardiac structure and function by maintaining the shapes of cells, transmitting mechanical/contractile forces from individual myocytes for coordinated contractions, and regulating elastic recoil during cavity filling (diastole) and contraction (systole) (11, 22) . In pathological conditions such as those seen with hypertension and heart failure, excessive deposition of collagen occurs throughout the myocardium (i.e., interstitial fibrosis). Excess fibrosis can lead to interruption of cell-cell connections and prevent coordinated contractions of the whole heart. The excess fibrosis also enhances tissue stiffness, which leads to impaired diastolic and systolic functions (5, 14, 15, 27) . Several growth factors have been identified as promoters of the excess deposition of cardiac collagens (3) . Experimental and clinical studies support a prominent role for ANG II in promoting the excess deposition of cardiac ECM proteins with disease (2, 25, 30) . Current therapies aim to block the action of ANG II as a means to reduce cardiac fibrosis. However, the identification of agents that may have direct anti-fibrotic actions is of great interest.
Adenosine (ADO) reportedly inhibits multiple CF functions including cell proliferation, protein, and collagen synthesis (6, 8 -10) . Pharmacological data, including our own (see Ref. 10a) , indicate that the effects are likely mediated by receptors of the A 2 subclass. Stimulation of A 2 receptors on adult rat CF leads to the elevation of cAMP and to antiproliferative and antifibrotic effects. In vivo studies using a rat model of myocardial infarction indicate that agents that increase endogenous ADO levels can, indeed, reduce scar tissue deposition (24) . Presumably, the inhibitory actions of ADO on fibroblast collagen production occur via elevation of cAMP, a supposition supported by the ability of forskolin (FSK) to inhibit serum-stimulated collagen synthesis (10a). Canonical pathways associated with downstream actions of ADO-induced increases in intracellular cAMP levels include the activation of protein kinase A (PKA), activation of cAMP response element, and activation of extracellular signal-regulated kinase 1/2 (ERK1/2) (23).
The objectives of this study were to identify mechanisms by which activation of A 2 receptors results in inhibition of collagen synthesis in cultured rat CF.
MATERIALS AND METHODS
ANG II was purchased from Sigma-Aldrich. 8-Bromoadenosine 3Ј,5Ј-cyclic monophosphothioate (Rp isomer) (Rp-8-Br-cAMPS), Sp-8-Br-cAMPS (Sp isomer), and 8-CPT-2Ј-O-Me-cAMP (CPT) were obtained from Alexis Biochemicals. Compound C was purchased from EMD-Biosciences Calbiochem. L- [2,3,4,5- 3 H]proline was purchased from PerkinElmer Life and Analytical Sciences. All other reagents used for the stated experiments were obtained as described in the related manuscript.
CF isolation and culture. Animal protocols were approved by the Institutional Animal Care and Use Committee of UCSD, which is accredited by AAALAC. Primary adult rat CF cultures were generated from ventricular tissues of 6-to 8-wk-old male Sprague-Dawley rats (250 -275 g) as previously described (see Ref. 10a 3 H]proline Ϯ pharmacological agents provide a treatment paradigm that meets these criteria; this protocol was used in the experiments reported below, unless otherwise noted. Antagonists were added 20 min before the addition of agonists in pharmacological experiments. Cell proliferation (total cell number) was not altered by ANG II or NECA (data not shown). Treatment (14 h) with ANG II increased total protein levels by only ϳ12%, ANG II ϩ NECA by 11%.
ERK 1/2 and Akt activation. After agonist stimulation, experiments were stopped by aspiration of media, a single rinse with PBS, and the addition of cold lysis buffer (50 mM Tris ⅐ HCl, 1 mM EGTA, 10 mM MgCl 2, 1% Triton X-100, 1 mM phenylmethlysulfonyl fluoride, 10 g/ml leupeptin, 10 mM NaF, 30 mM ␤-glycerolphosphate, pH 7.0). Equal amounts of total protein were processed by SDS-PAGE. Phospho-ERK1/2, total ERK1/2, phospho-Akt, or total Akt were detected on Western blots by immunochemiluminescence (NEB Cell Signaling Technology and Amersham Life Sciences).
Analysis of data. All data were graphed and analyzed using Prism 3.0 (GraphPad Software, San Diego, CA). All data are reported as means Ϯ SE. Statistical analysis of the data was performed using Student's paired t-test, Student's unpaired t-test, analysis of variance (ANOVA) followed by Bonferroni's multiple comparison posttest, or two-way ANOVA. Significance was defined as P Ͻ 0.05.
RESULTS

ADO effects on ANG II-induced collagen synthesis.
Stimulation of CF with 100 nM ANG II significantly increased incorporation by [ 3 H]proline into protein by ϳ70% ( cAMP, PKA, and ADO-mediated regulation of collagen synthesis. FSK, a direct activator of adenylyl cyclase (AC), mimicked ADO-mediated inhibition of ANG II-stimulated collagen synthesis ( Fig. 2A) . To determine the role of PKA activation in ADO-inhibited collagen synthesis, we employed the specific PKA activator Sp-8-Br-cAMPS. Treatment of CF with 30 M Sp-8-Br-cAMPS did not inhibit ANG II-stimulated collagen synthesis (Fig. 2B) . The same concentration of Sp-8-Br-cAMP did, however, cause phosphorylation of glycogen synthase kinase 3-␤ (GSK-3␤) at Ser9, a known substrate of PKA (16) , indicating that Sp-8-Br-cAMP does activate PKA in CF (increase in phosphorylation over control, 25 Ϯ 6%, n ϭ 14, P Ͻ 0.05, after 30 min treatment with Sp-8-Br-cAMP at 30 mM). The inability of Sp-8-Br-cAMPS to mimic ADO suggested that activation of PKA by cAMP is not involved in the mechanism by which ADO inhibits ANG II-stimulated collagen synthesis.
To confirm the lack of involvement of PKA, we performed experiments employing the PKA inhibitors N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H89) and Rp-8-Br-cAMPS. Neither H89 nor Rp-8-Br-cAMPS reversed the effect of NECA to inhibit ANG II-stimulated collagen synthesis (Fig. 2, C and D) . Control experiments demonstrated that these concentrations of H89 and Rp-8-Br-cAMPS significantly inhibit the phosphorylation of GSK-3␤ that occurs in response to the elevation of cAMP that accompanies exposure to FSK (10 M for 15 min). Thus we concluded that the effect of ADO agonists to inhibit collagen synthesis involves cAMP but is PKA independent.
ADO, AMPK, cAMP-Epac-PI3K, and collagen synthesis.
We investigated the possible involvement of two pathways downstream from AR-induced cAMP synthesis, adenosine monophosphate kinase (AMPK) and exchange factor directly activated by cAMP (Epac). Cellular phosphodiesterase(s) (PDEs) are known to convert cAMP to AMP, which in turn can activate AMPK (4). In CF, AMP production from this pathway can be significant (12) 
To assess the involvement of AMPK, CF were pretreated with 5 M compound C, an AMPK inhibitor, for 20 min, followed by treatment with 100 nM ANG II Ϯ 100 M NECA for 14 h to assess [ 3 H]proline incorporation. Pretreatment with compound C did not relieve the inhibition by NECA of ANG II-induced proline incorporation into protein (data not shown), suggesting that AMPK is not involved in mediating the effects of NECA. The involvement of Epac was evaluated by using the specific activator CPT. CPT significantly inhibited proline incorporation induced by 100 nM ANG II (Fig. 3A) . GSK-3␤ phosphorylation, used as a surrogate for PKA activation, was not increased by CPT treatment; in fact, CPT reduced basal levels of GSK-3␤ phosphorylation (to 80 Ϯ 3% of control, n ϭ 14, P Ͻ 0.05).
As a further test of the specificity of CPT, we assessed its effect on ERK1/2, which is activated by ADO agonists. CPT promoted phosphorylation of ERK1/2 in a time-dependent manner (Fig. 3B) . A concentration of H89 that inhibited GSK3-␤ phosphorylation by PKA did not block the ability of CPT to activate ERK1/2 (data not shown). These data suggest that ERK1/2 activation by ADO agonists reflects a cAMPdependent, PKA-independent event that occurs through Epac and that the effect of ADO agonists to inhibit ANG II-stimulated collagen synthesis occurs via a cAMP-Epac pathway.
Two pharmacological agents were used to determine whether the effects of ADO on ANG II-stimulated collagen synthesis involve ERK1/2 or PI3K: LY-294002 (LY), an inhibitor of PI3K, and PD-98059 (PD), an inhibitor of mitogen-activated protein kinase kinase (MEK), the protein kinase that phosphorylates ERK1/2. Treatment with LY relieved the inhibitory effect of NECA on ANG II-stimulated collagen synthesis (Fig.  4A) ; treatment with PD did not alter the effects of NECA (Fig.  4B) . To verify that PD actually inhibited ERK1/2 activation under these conditions, we assessed the capacity of PD to inhibit LPA-stimulated ERK1/2 phosphorylation. LPA significantly increased ERK1/2 phosphorylation (see above) and pretreatment with PD reduced this increase to control levels. Thus the activation of PI3K, but not of MEK or ERK1/2, appears involved in NECA-mediated inhibition of ANG IIstimulated collagen synthesis.
These data suggest that PI3K may be activated as a consequence of Epac activation and that inhibition of collagen synthesis occurs downstream of Epac via PI3K. Other data support this possibility: blockade of PI3K activity with LY relieved the inhibitory effect of Epac activation (in response to CPT treatment) on ANG II-stimulated proline incorporation into protein (Fig. 5) . Treatment of cells with NECA also caused the time-dependent phosphorylation of protein kinase B (PKB) (AKT) (Fig. 6) , an effect that LY, the PI3K inhibitor, significantly inhibited (AKT phosphorylation as fold over control ϭ 1: NECA, 1.7 Ϯ 0.2; NECA ϩ LY, 1.0 Ϯ 0.2, P Ͻ 0.01 for effects of NECA and LY). This suggests that NECA activates PKB via PI3K activation, and that ADO agonists can act via PKB to downregulate ANG II-induced collagen synthesis.
DISCUSSION
We have developed an experimental paradigm that avoids some of the problems generally encountered in studies of collagen synthesis by cultured fibroblasts. Most in vitro models of cardiac fibrosis assess changes in collagen synthesis via [ 3 H]proline incorporation, and the majority of these studies use fetal bovine serum as the stimulus to increase collagen synthesis (8) . Although serum is an excellent stimulus for cell growth and collagen synthesis, it is inherently complex and contains many growth factors, including LPA, angiotensin, and catecholamines. We have developed a serum-free protocol in which these confounding factors are removed. Second, we have employed ANG II as the "profibrotic" stimulus. The role that ANG II plays in modulating pathological cardiac remodeling and fibrosis is supported by extensive studies performed in vitro, in vivo, and by clinical trials (2, 25, 30) . In this study, we utilized ANG II treatment of isolated CF as the means to stimulate incorporation of proline into collagen to examine the signaling mechanisms by which ADO may counteract its effects. The protocol that we have developed provides useful data within 14 h, thereby avoiding issues of long-term cell growth encountered in traditional protocols (48 -72 h).
In cultured rat CF, ADO inhibits functions known to be associated with fibrosis. Both exogenous and endogenous ADO decrease serum-induced proliferation measured by (8, 9, 24) . Available evidence suggests that inhibition of most, if not all, of these functions by ADO occurs via A 2 Rs (6, 8, 9) . Indeed, the data in our accompanying paper (10a) firmly support this conjecture. Although most workers agree that the effects of ADO likely occur via cAMP, the direct pathway by which ADO-stimulated cAMP acts is not known. Activation of PKA is the best-known pathway by which cAMP mediates effects; however, cAMP can interact with other downstream effectors: cyclic nucleotidegated ion channels (CNGs), Epac, and PDEs. CNGs, while found in nonneuronal cell types, are predominantly located in photoreceptor cells and olfactory sensory neurons (1, 17) . Whereas it is not likely that CNGs are functioning in CF, Epac is present. Epac, functions as a guanine exchange factor for the small GTPases Rap1 and Rap2 (7). Activation of Rap by Epac can lead to further signaling and activation of pathways involving ERK1/2 or PI3K (26, 28) . Indeed, overexpression of Epac in the heart inhibits collagen synthesis stimulated by transforming growth factor-␤ (29) . Additionally, an elevation in cAMP by ADO could conceivably lead to downstream activation of AMPK, since degradation of cAMP by PDEs in CF is robust and could produce sufficient 5Ј-AMP when the G s -AC pathway is modestly stimulated (12) . AMPK functions to decrease anabolic pathways such as protein synthesis (13, 18) . Thus the examination of mechanisms of ADO- Fig. 7 . Proposed signaling pathway for adenosine-mediated inhibition of collagen production. See text for more information. mediated decreases in collagen synthesis with ADO also required assessing the involvement of downstream effects of Epac and AMPK. There is precedent for these possibilities. In lung fibroblasts the stimulation of the cells with agents that elevate cAMP led to the inhibition of collagen synthesis (19) and proliferation (21) , and the anti-proliferative effects were mediated by Epac rather than the classical PKA pathway. Interestingly, inhibitory effects of cAMP on collagen I gene expression appeared not mediated by Epac but by alternate pathways.
We found that stimulation of AMPK with CPT increased ERK1/2 phosphorylation in CFs in accord with previous data that cAMP elevating agents (e.g., CADO, NECA, FSK, and 8-Br-cAMP) all increase ERK1/2 phosphorylation in these cells. Taken together, this indicates that A 2 R, via elevation of cAMP, can activate Epac, leading to ERK1/2 activation in CFs. Although NECA and CPT both activated ERK1/2, inhibition of MEK1/2 (the upstream kinase that phosphorylates ERK1/2) with PD-98059 had no effect on relieving the NECA-mediated inhibition of ANG II-induced [ 3 H]proline incorporation. Although ERK1/2 is activated by this ADO-cAMP-Epac signaling pathway, this pathway appears to play no role in the ADO-mediated inhibition of collagen production. However, ERK1/2 activation by cAMP/Epac and by a multiplicity of signals acting through PKC and Ca 2ϩ appears to mediate some of the proliferative responses to ANG II in CF (20) .
Our experiments verify the involvement of cAMP in mediating the inhibition of CF collagen synthesis by ADO: FSK mimics the effect of NECA on [
3 H]proline incorporation. However, the inability of PKA activation (by Sp-8-Br-CAMPS) to inhibit ANG II-induced [ 3 H]proline incorporation and the lack of effect of PKA inhibitors (H89 or Rp-8-Br-cAMPS) on the actions of NECA indicate that the inhibitory effects of NECA do not occur via activation of PKA. Likewise, the lack of effect of inhibitors of AMPK and ERK1/2 on NECA-inhibited [ 3 H]proline incorporation indicates that NECA is not working to inhibit collagen levels via either of these enzymes. Since activation of Epac (by 8-CPT-2Ј-O-Me-cAMP) mimics the effects of NECA on ANG II-stimulated [ 3 H]proline incorporation, we predict that one major inhibitory mechanism by which NECA regulates collagen synthesis is due to Epac activation. However, further verification of the role of Epac by other means (such as gene silencing techniques to reduce cellular Epac1 and/or Epac2) is warranted, so as to verify independently whether the effects of adenosine agonists on collagen synthesis are dependent on Epac activity as the pharmacological data suggest. The ability of PI3K inhibition to relieve the inhibition of NECA on ANG II-induced [ 3 H]proline incorporation also indicates that NECA exerts its inhibitory effects on collagen levels through a pathway that involves PI3K activation. This is supported by the finding that PI3K inhibition also relieves the inhibition of CPT on ANG II-mediated increases in [ 3 H]proline incorporation. Pharmacological data suggest the involvement of PKB downstream from PI3K. Thus a new hypothesis for the mechanism of ADO-mediated inhibition of collagen production is emerging (see Fig. 7 ): ADO activates A 2 Rs leading to an accumulation of intracellular cAMP that activates Epac and PI3K, and possibly PKB, which in turn leads to a decrease in total collagen protein levels; growth control may occur via ERK1/2 (20) .
The definition of this pathway provides the framework for new points at which to pharmacologically regulate collagen synthesis. In particular, in the setting of postinfarction cardiac remodeling, knowledge of this pathway may permit manipulation of collagen synthesis so that wound healing (scarring) occurs but collagen deposition does not progress to excessive levels.
